世界のインフルエンザ (Flu) 抗ウイルス薬市場規模・現状・予測（2021年-2027年）

• 英文タイトル：Global Influenza (Flu) Antiviral Drugs Market Size, Status and Forecast 2021-2027

• レポートコード：QFJ1-5801 • 出版社/出版日：QYResearch / 2021年6月 ※2024年版があります。お問い合わせください。 • レポート形態：英文、PDF、121ページ • 納品方法：Eメール（納期：3日） • 産業分類：医薬品

• 販売価格（消費税別）

Single User	￥585,000 (USD3,900)	▷ お問い合わせ
Multi User	￥877,500 (USD5,850)	▷ お問い合わせ

• ご注文方法：お問い合わせフォーム記入又はEメールでご連絡ください。
• お支払方法：銀行振込（納品後、ご請求書送付）

---

レポート概要

---

QYResearch社発行の本調査レポートでは、インフルエンザ (Flu) 抗ウイルス薬の世界市場（2016年～2027年）を対象に調査し、市場動向、主要企業の市場シェア、種類別市場規模（浸透＆剥離阻害剤、DNAポリメラーゼ阻害剤、逆転写酵素阻害剤、タンパク質阻害剤、ノイラミニダーゼ阻害剤、広域スペクトル抗ウイルス薬）、用途別市場規模（病院、診療所、家庭用、その他）、主要地域別市場規模（北米、アメリカ、欧州、アジア、日本、中国、韓国、インド、東南アジア、中南米、中東、アフリカ等）、企業情報などをまとめております。 ・市場概要 ・インフルエンザ (Flu) 抗ウイルス薬の市場動向 ・企業の競争状況、市場シェア ・インフルエンザ (Flu) 抗ウイルス薬の種類別市場規模と予測2016-2027（浸透＆剥離阻害剤、DNAポリメラーゼ阻害剤、逆転写酵素阻害剤、タンパク質阻害剤、ノイラミニダーゼ阻害剤、広域スペクトル抗ウイルス薬） ・インフルエンザ (Flu) 抗ウイルス薬の用途別市場規模と予測2016-2027（病院、診療所、家庭用、その他） ・インフルエンザ (Flu) 抗ウイルス薬の北米市場規模2016-2027（アメリカ、カナダ） ・インフルエンザ (Flu) 抗ウイルス薬の欧州市場規模2016-2027（ドイツ、フランス、イギリス等） ・インフルエンザ (Flu) 抗ウイルス薬のアジア市場規模2016-2027（日本、中国、韓国、インド、東南アジア等） ・インフルエンザ (Flu) 抗ウイルス薬の中南米市場規模2016-2027（メキシコ、ブラジル） ・インフルエンザ (Flu) 抗ウイルス薬の中東・アフリカ市場規模2016-2027（トルコ、サウジアラビア等） ・主要企業情報（Pfizer、Roche、Sanofi、Johnson & Johnson、Merck & Co. (MSD)、Novartis、AbbVie、Gilead Sciences、GlaxoSmithKline (GSK)、Amgen、AstraZeneca、Bristol-Myers Squibb、Eli Lilly、Teva、Bayer、Novo Nordisk、Allergan、Takeda、Boehringer Ingelheim） ・結論

Antiviral drugs are a class of drugs for the specific treatment of viral infections.

Market Analysis and Insights: Global Influenza (Flu) Antiviral Drugs Market
The global Influenza (Flu) Antiviral Drugs market size is projected to reach US$ XX million by 2027, from US$ XX million in 2020, at a CAGR of XX% during 2021-2027.
With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global Influenza (Flu) Antiviral Drugs market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global Influenza (Flu) Antiviral Drugs market in terms of revenue.
On the whole, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global Influenza (Flu) Antiviral Drugs market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global Influenza (Flu) Antiviral Drugs market.

Global Influenza (Flu) Antiviral Drugs Scope and Market Size
Influenza (Flu) Antiviral Drugs market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global Influenza (Flu) Antiviral Drugs market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2016-2027.

Segment by Type
Penetration and Dehulling Inhibitors
DNA Polymerase Inhibitors
Reverse Transcriptase Inhibitors
Protein Inhibitors
Neuraminidase Inhibitors
Broad-spectrum Antiviral Drugs

Segment by Application
Hospital
Clinic
Household
Others

By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA

By Company
Pfizer
Roche
Sanofi
Johnson & Johnson
Merck & Co. (MSD)
Novartis
AbbVie
Gilead Sciences
GlaxoSmithKline (GSK)
Amgen
AstraZeneca
Bristol-Myers Squibb
Eli Lilly
Teva
Bayer
Novo Nordisk
Allergan
Takeda
Boehringer Ingelheim

レポート目次

---

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Influenza (Flu) Antiviral Drugs Market Size Growth Rate by Type: 2016 VS 2021 VS 2027
1.2.2 Penetration and Dehulling Inhibitors
1.2.3 DNA Polymerase Inhibitors
1.2.4 Reverse Transcriptase Inhibitors
1.2.5 Protein Inhibitors
1.2.6 Neuraminidase Inhibitors
1.2.7 Broad-spectrum Antiviral Drugs
1.3 Market by Application
1.3.1 Global Influenza (Flu) Antiviral Drugs Market Share by Application: 2016 VS 2021 VS 2027
1.3.2 Hospital
1.3.3 Clinic
1.3.4 Household
1.3.5 Others
1.4 Study Objectives
1.5 Years Considered

2 Global Growth Trends
2.1 Global Influenza (Flu) Antiviral Drugs Market Perspective (2016-2027)
2.2 Influenza (Flu) Antiviral Drugs Growth Trends by Regions
2.2.1 Influenza (Flu) Antiviral Drugs Market Size by Regions: 2016 VS 2021 VS 2027
2.2.2 Influenza (Flu) Antiviral Drugs Historic Market Share by Regions (2016-2021)
2.2.3 Influenza (Flu) Antiviral Drugs Forecasted Market Size by Regions (2022-2027)
2.3 Influenza (Flu) Antiviral Drugs Industry Dynamic
2.3.1 Influenza (Flu) Antiviral Drugs Market Trends
2.3.2 Influenza (Flu) Antiviral Drugs Market Drivers
2.3.3 Influenza (Flu) Antiviral Drugs Market Challenges
2.3.4 Influenza (Flu) Antiviral Drugs Market Restraints

3 Competition Landscape by Key Players
3.1 Global Top Influenza (Flu) Antiviral Drugs Players by Revenue
3.1.1 Global Top Influenza (Flu) Antiviral Drugs Players by Revenue (2016-2021)
3.1.2 Global Influenza (Flu) Antiviral Drugs Revenue Market Share by Players (2016-2021)
3.2 Global Influenza (Flu) Antiviral Drugs Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.3 Players Covered: Ranking by Influenza (Flu) Antiviral Drugs Revenue
3.4 Global Influenza (Flu) Antiviral Drugs Market Concentration Ratio
3.4.1 Global Influenza (Flu) Antiviral Drugs Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Influenza (Flu) Antiviral Drugs Revenue in 2020
3.5 Influenza (Flu) Antiviral Drugs Key Players Head office and Area Served
3.6 Key Players Influenza (Flu) Antiviral Drugs Product Solution and Service
3.7 Date of Enter into Influenza (Flu) Antiviral Drugs Market
3.8 Mergers & Acquisitions, Expansion Plans

4 Influenza (Flu) Antiviral Drugs Breakdown Data by Type
4.1 Global Influenza (Flu) Antiviral Drugs Historic Market Size by Type (2016-2021)
4.2 Global Influenza (Flu) Antiviral Drugs Forecasted Market Size by Type (2022-2027)

5 Influenza (Flu) Antiviral Drugs Breakdown Data by Application
5.1 Global Influenza (Flu) Antiviral Drugs Historic Market Size by Application (2016-2021)
5.2 Global Influenza (Flu) Antiviral Drugs Forecasted Market Size by Application (2022-2027)

6 North America
6.1 North America Influenza (Flu) Antiviral Drugs Market Size (2016-2027)
6.2 North America Influenza (Flu) Antiviral Drugs Market Size by Type
6.2.1 North America Influenza (Flu) Antiviral Drugs Market Size by Type (2016-2021)
6.2.2 North America Influenza (Flu) Antiviral Drugs Market Size by Type (2022-2027)
6.2.3 North America Influenza (Flu) Antiviral Drugs Market Size by Type (2016-2027)
6.3 North America Influenza (Flu) Antiviral Drugs Market Size by Application
6.3.1 North America Influenza (Flu) Antiviral Drugs Market Size by Application (2016-2021)
6.3.2 North America Influenza (Flu) Antiviral Drugs Market Size by Application (2022-2027)
6.3.3 North America Influenza (Flu) Antiviral Drugs Market Size by Application (2016-2027)
6.4 North America Influenza (Flu) Antiviral Drugs Market Size by Country
6.4.1 North America Influenza (Flu) Antiviral Drugs Market Size by Country (2016-2021)
6.4.2 North America Influenza (Flu) Antiviral Drugs Market Size by Country (2022-2027)
6.4.3 United States
6.4.4 Canada

7 Europe
7.1 Europe Influenza (Flu) Antiviral Drugs Market Size (2016-2027)
7.2 Europe Influenza (Flu) Antiviral Drugs Market Size by Type
7.2.1 Europe Influenza (Flu) Antiviral Drugs Market Size by Type (2016-2021)
7.2.2 Europe Influenza (Flu) Antiviral Drugs Market Size by Type (2022-2027)
7.2.3 Europe Influenza (Flu) Antiviral Drugs Market Size by Type (2016-2027)
7.3 Europe Influenza (Flu) Antiviral Drugs Market Size by Application
7.3.1 Europe Influenza (Flu) Antiviral Drugs Market Size by Application (2016-2021)
7.3.2 Europe Influenza (Flu) Antiviral Drugs Market Size by Application (2022-2027)
7.3.3 Europe Influenza (Flu) Antiviral Drugs Market Size by Application (2016-2027)
7.4 Europe Influenza (Flu) Antiviral Drugs Market Size by Country
7.4.1 Europe Influenza (Flu) Antiviral Drugs Market Size by Country (2016-2021)
7.4.2 Europe Influenza (Flu) Antiviral Drugs Market Size by Country (2022-2027)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
7.4.8 Nordic

8 Asia-Pacific
8.1 Asia-Pacific Influenza (Flu) Antiviral Drugs Market Size (2016-2027)
8.2 Asia-Pacific Influenza (Flu) Antiviral Drugs Market Size by Type
8.2.1 Asia-Pacific Influenza (Flu) Antiviral Drugs Market Size by Type (2016-2021)
8.2.2 Asia-Pacific Influenza (Flu) Antiviral Drugs Market Size by Type (2022-2027)
8.2.3 Asia-Pacific Influenza (Flu) Antiviral Drugs Market Size by Type (2016-2027)
8.3 Asia-Pacific Influenza (Flu) Antiviral Drugs Market Size by Application
8.3.1 Asia-Pacific Influenza (Flu) Antiviral Drugs Market Size by Application (2016-2021)
8.3.2 Asia-Pacific Influenza (Flu) Antiviral Drugs Market Size by Application (2022-2027)
8.3.3 Asia-Pacific Influenza (Flu) Antiviral Drugs Market Size by Application (2016-2027)
8.4 Asia-Pacific Influenza (Flu) Antiviral Drugs Market Size by Region
8.4.1 Asia-Pacific Influenza (Flu) Antiviral Drugs Market Size by Region (2016-2021)
8.4.2 Asia-Pacific Influenza (Flu) Antiviral Drugs Market Size by Region (2022-2027)
8.4.3 China
8.4.4 Japan
8.4.5 South Korea
8.4.6 Southeast Asia
8.4.7 India
8.4.8 Australia

9 Latin America
9.1 Latin America Influenza (Flu) Antiviral Drugs Market Size (2016-2027)
9.2 Latin America Influenza (Flu) Antiviral Drugs Market Size by Type
9.2.1 Latin America Influenza (Flu) Antiviral Drugs Market Size by Type (2016-2021)
9.2.2 Latin America Influenza (Flu) Antiviral Drugs Market Size by Type (2022-2027)
9.2.3 Latin America Influenza (Flu) Antiviral Drugs Market Size by Type (2016-2027)
9.3 Latin America Influenza (Flu) Antiviral Drugs Market Size by Application
9.3.1 Latin America Influenza (Flu) Antiviral Drugs Market Size by Application (2016-2021)
9.3.2 Latin America Influenza (Flu) Antiviral Drugs Market Size by Application (2022-2027)
9.3.3 Latin America Influenza (Flu) Antiviral Drugs Market Size by Application (2016-2027)
9.4 Latin America Influenza (Flu) Antiviral Drugs Market Size by Country
9.4.1 Latin America Influenza (Flu) Antiviral Drugs Market Size by Country (2016-2021)
9.4.2 Latin America Influenza (Flu) Antiviral Drugs Market Size by Country (2022-2027)
9.4.3 Mexico
9.4.4 Brazil

10 Middle East & Africa
10.1 Middle East & Africa Influenza (Flu) Antiviral Drugs Market Size (2016-2027)
10.2 Middle East & Africa Influenza (Flu) Antiviral Drugs Market Size by Type
10.2.1 Middle East & Africa Influenza (Flu) Antiviral Drugs Market Size by Type (2016-2021)
10.2.2 Middle East & Africa Influenza (Flu) Antiviral Drugs Market Size by Type (2022-2027)
10.2.3 Middle East & Africa Influenza (Flu) Antiviral Drugs Market Size by Type (2016-2027)
10.3 Middle East & Africa Influenza (Flu) Antiviral Drugs Market Size by Application
10.3.1 Middle East & Africa Influenza (Flu) Antiviral Drugs Market Size by Application (2016-2021)
10.3.2 Middle East & Africa Influenza (Flu) Antiviral Drugs Market Size by Application (2022-2027)
10.3.3 Middle East & Africa Influenza (Flu) Antiviral Drugs Market Size by Application (2016-2027)
10.4 Middle East & Africa Influenza (Flu) Antiviral Drugs Market Size by Country
10.4.1 Middle East & Africa Influenza (Flu) Antiviral Drugs Market Size by Country (2016-2021)
10.4.2 Middle East & Africa Influenza (Flu) Antiviral Drugs Market Size by Country (2022-2027)
10.4.3 Turkey
10.4.4 Saudi Arabia
10.4.5 UAE

11 Key Players Profiles
11.1 Pfizer
11.1.1 Pfizer Company Details
11.1.2 Pfizer Business Overview
11.1.3 Pfizer Influenza (Flu) Antiviral Drugs Introduction
11.1.4 Pfizer Revenue in Influenza (Flu) Antiviral Drugs Business (2016-2021)
11.1.5 Pfizer Recent Development
11.2 Roche
11.2.1 Roche Company Details
11.2.2 Roche Business Overview
11.2.3 Roche Influenza (Flu) Antiviral Drugs Introduction
11.2.4 Roche Revenue in Influenza (Flu) Antiviral Drugs Business (2016-2021)
11.2.5 Roche Recent Development
11.3 Sanofi
11.3.1 Sanofi Company Details
11.3.2 Sanofi Business Overview
11.3.3 Sanofi Influenza (Flu) Antiviral Drugs Introduction
11.3.4 Sanofi Revenue in Influenza (Flu) Antiviral Drugs Business (2016-2021)
11.3.5 Sanofi Recent Development
11.4 Johnson & Johnson
11.4.1 Johnson & Johnson Company Details
11.4.2 Johnson & Johnson Business Overview
11.4.3 Johnson & Johnson Influenza (Flu) Antiviral Drugs Introduction
11.4.4 Johnson & Johnson Revenue in Influenza (Flu) Antiviral Drugs Business (2016-2021)
11.4.5 Johnson & Johnson Recent Development
11.5 Merck & Co. (MSD)
11.5.1 Merck & Co. (MSD) Company Details
11.5.2 Merck & Co. (MSD) Business Overview
11.5.3 Merck & Co. (MSD) Influenza (Flu) Antiviral Drugs Introduction
11.5.4 Merck & Co. (MSD) Revenue in Influenza (Flu) Antiviral Drugs Business (2016-2021)
11.5.5 Merck & Co. (MSD) Recent Development
11.6 Novartis
11.6.1 Novartis Company Details
11.6.2 Novartis Business Overview
11.6.3 Novartis Influenza (Flu) Antiviral Drugs Introduction
11.6.4 Novartis Revenue in Influenza (Flu) Antiviral Drugs Business (2016-2021)
11.6.5 Novartis Recent Development
11.7 AbbVie
11.7.1 AbbVie Company Details
11.7.2 AbbVie Business Overview
11.7.3 AbbVie Influenza (Flu) Antiviral Drugs Introduction
11.7.4 AbbVie Revenue in Influenza (Flu) Antiviral Drugs Business (2016-2021)
11.7.5 AbbVie Recent Development
11.8 Gilead Sciences
11.8.1 Gilead Sciences Company Details
11.8.2 Gilead Sciences Business Overview
11.8.3 Gilead Sciences Influenza (Flu) Antiviral Drugs Introduction
11.8.4 Gilead Sciences Revenue in Influenza (Flu) Antiviral Drugs Business (2016-2021)
11.8.5 Gilead Sciences Recent Development
11.9 GlaxoSmithKline (GSK)
11.9.1 GlaxoSmithKline (GSK) Company Details
11.9.2 GlaxoSmithKline (GSK) Business Overview
11.9.3 GlaxoSmithKline (GSK) Influenza (Flu) Antiviral Drugs Introduction
11.9.4 GlaxoSmithKline (GSK) Revenue in Influenza (Flu) Antiviral Drugs Business (2016-2021)
11.9.5 GlaxoSmithKline (GSK) Recent Development
11.10 Amgen
11.10.1 Amgen Company Details
11.10.2 Amgen Business Overview
11.10.3 Amgen Influenza (Flu) Antiviral Drugs Introduction
11.10.4 Amgen Revenue in Influenza (Flu) Antiviral Drugs Business (2016-2021)
11.10.5 Amgen Recent Development
11.11 AstraZeneca
11.11.1 AstraZeneca Company Details
11.11.2 AstraZeneca Business Overview
11.11.3 AstraZeneca Influenza (Flu) Antiviral Drugs Introduction
11.11.4 AstraZeneca Revenue in Influenza (Flu) Antiviral Drugs Business (2016-2021)
11.11.5 AstraZeneca Recent Development
11.12 Bristol-Myers Squibb
11.12.1 Bristol-Myers Squibb Company Details
11.12.2 Bristol-Myers Squibb Business Overview
11.12.3 Bristol-Myers Squibb Influenza (Flu) Antiviral Drugs Introduction
11.12.4 Bristol-Myers Squibb Revenue in Influenza (Flu) Antiviral Drugs Business (2016-2021)
11.12.5 Bristol-Myers Squibb Recent Development
11.13 Eli Lilly
11.13.1 Eli Lilly Company Details
11.13.2 Eli Lilly Business Overview
11.13.3 Eli Lilly Influenza (Flu) Antiviral Drugs Introduction
11.13.4 Eli Lilly Revenue in Influenza (Flu) Antiviral Drugs Business (2016-2021)
11.13.5 Eli Lilly Recent Development
11.14 Teva
11.14.1 Teva Company Details
11.14.2 Teva Business Overview
11.14.3 Teva Influenza (Flu) Antiviral Drugs Introduction
11.14.4 Teva Revenue in Influenza (Flu) Antiviral Drugs Business (2016-2021)
11.14.5 Teva Recent Development
11.15 Bayer
11.15.1 Bayer Company Details
11.15.2 Bayer Business Overview
11.15.3 Bayer Influenza (Flu) Antiviral Drugs Introduction
11.15.4 Bayer Revenue in Influenza (Flu) Antiviral Drugs Business (2016-2021)
11.15.5 Bayer Recent Development
11.16 Novo Nordisk
11.16.1 Novo Nordisk Company Details
11.16.2 Novo Nordisk Business Overview
11.16.3 Novo Nordisk Influenza (Flu) Antiviral Drugs Introduction
11.16.4 Novo Nordisk Revenue in Influenza (Flu) Antiviral Drugs Business (2016-2021)
11.16.5 Novo Nordisk Recent Development
11.17 Allergan
11.17.1 Allergan Company Details
11.17.2 Allergan Business Overview
11.17.3 Allergan Influenza (Flu) Antiviral Drugs Introduction
11.17.4 Allergan Revenue in Influenza (Flu) Antiviral Drugs Business (2016-2021)
11.17.5 Allergan Recent Development
11.18 Takeda
11.18.1 Takeda Company Details
11.18.2 Takeda Business Overview
11.18.3 Takeda Influenza (Flu) Antiviral Drugs Introduction
11.18.4 Takeda Revenue in Influenza (Flu) Antiviral Drugs Business (2016-2021)
11.18.5 Takeda Recent Development
11.18 Boehringer Ingelheim
.1 Boehringer Ingelheim Company Details
.2 Boehringer Ingelheim Business Overview
.3 Boehringer Ingelheim Influenza (Flu) Antiviral Drugs Introduction
.4 Boehringer Ingelheim Revenue in Influenza (Flu) Antiviral Drugs Business (2016-2021)
.5 Boehringer Ingelheim Recent Development

12 Analyst’s Viewpoints/Conclusions

13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details

List of Tables
Table 1. Global Influenza (Flu) Antiviral Drugs Market Size Growth Rate by Type (US$ Million):2016 VS 2021 VS 2027
Table 2. Key Players of Penetration and Dehulling Inhibitors
Table 3. Key Players of DNA Polymerase Inhibitors
Table 4. Key Players of Reverse Transcriptase Inhibitors
Table 5. Key Players of Protein Inhibitors
Table 6. Key Players of Neuraminidase Inhibitors
Table 7. Key Players of Broad-spectrum Antiviral Drugs
Table 8. Global Influenza (Flu) Antiviral Drugs Market Size Growth by Application (US$ Million): 2016 VS 2021 VS 2027
Table 9. Global Influenza (Flu) Antiviral Drugs Market Size by Regions (US$ Million): 2016 VS 2021 VS 2027
Table 10. Global Influenza (Flu) Antiviral Drugs Market Size by Regions (2016-2021) & (US$ Million)
Table 11. Global Influenza (Flu) Antiviral Drugs Market Share by Regions (2016-2021)
Table 12. Global Influenza (Flu) Antiviral Drugs Forecasted Market Size by Regions (2022-2027) & (US$ Million)
Table 13. Global Influenza (Flu) Antiviral Drugs Market Share by Regions (2022-2027)
Table 14. Influenza (Flu) Antiviral Drugs Market Trends
Table 15. Influenza (Flu) Antiviral Drugs Market Drivers
Table 16. Influenza (Flu) Antiviral Drugs Market Challenges
Table 17. Influenza (Flu) Antiviral Drugs Market Restraints
Table 18. Global Influenza (Flu) Antiviral Drugs Revenue by Players (2016-2021) & (US$ Million)
Table 19. Global Influenza (Flu) Antiviral Drugs Market Share by Players (2016-2021)
Table 20. Global Top Influenza (Flu) Antiviral Drugs Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Influenza (Flu) Antiviral Drugs as of 2020)
Table 21. Ranking of Global Top Influenza (Flu) Antiviral Drugs Companies by Revenue (US$ Million) in 2020
Table 22. Global 5 Largest Players Market Share by Influenza (Flu) Antiviral Drugs Revenue (CR5 and HHI) & (2016-2021)
Table 23. Key Players Headquarters and Area Served
Table 24. Key Players Influenza (Flu) Antiviral Drugs Product Solution and Service
Table 25. Date of Enter into Influenza (Flu) Antiviral Drugs Market
Table 26. Mergers & Acquisitions, Expansion Plans
Table 27. Global Influenza (Flu) Antiviral Drugs Market Size by Type (2016-2021) (US$ Million)
Table 28. Global Influenza (Flu) Antiviral Drugs Revenue Market Share by Type (2016-2021)
Table 29. Global Influenza (Flu) Antiviral Drugs Forecasted Market Size by Type (2022-2027) (US$ Million)
Table 30. Global Influenza (Flu) Antiviral Drugs Revenue Market Share by Type (2022-2027) & (US$ Million)
Table 31. Global Influenza (Flu) Antiviral Drugs Market Size Share by Application (2016-2021) & (US$ Million)
Table 32. Global Influenza (Flu) Antiviral Drugs Revenue Market Share by Application (2016-2021)
Table 33. Global Influenza (Flu) Antiviral Drugs Forecasted Market Size by Application (2022-2027) (US$ Million)
Table 34. Global Influenza (Flu) Antiviral Drugs Revenue Market Share by Application (2022-2027) & (US$ Million)
Table 35. North America Influenza (Flu) Antiviral Drugs Market Size by Type (2016-2021) (US$ Million)
Table 36. North America Influenza (Flu) Antiviral Drugs Market Size by Type (2022-2027) & (US$ Million)
Table 37. North America Influenza (Flu) Antiviral Drugs Market Size by Application (2016-2021) (US$ Million)
Table 38. North America Influenza (Flu) Antiviral Drugs Market Size by Application (2022-2027) & (US$ Million)
Table 39. North America Influenza (Flu) Antiviral Drugs Market Size by Country (2016-2021) & (US$ Million)
Table 40. North America Influenza (Flu) Antiviral Drugs Market Size by Country (2022-2027) & (US$ Million)
Table 41. Europe Influenza (Flu) Antiviral Drugs Market Size by Type (2016-2021) (US$ Million)
Table 42. Europe Influenza (Flu) Antiviral Drugs Market Size by Type (2022-2027) & (US$ Million)
Table 43. Europe Influenza (Flu) Antiviral Drugs Market Size by Application (2016-2021) (US$ Million)
Table 44. Europe Influenza (Flu) Antiviral Drugs Market Size by Application (2022-2027) & (US$ Million)
Table 45. Europe Influenza (Flu) Antiviral Drugs Market Size by Country (2016-2021) & (US$ Million)
Table 46. Europe Influenza (Flu) Antiviral Drugs Market Size by Country (2022-2027) & (US$ Million)
Table 47. Asia-Pacific Influenza (Flu) Antiviral Drugs Market Size by Type (2016-2021) (US$ Million)
Table 48. Asia-Pacific Influenza (Flu) Antiviral Drugs Market Size by Type (2022-2027) & (US$ Million)
Table 49. Asia-Pacific Influenza (Flu) Antiviral Drugs Market Size by Application (2016-2021) (US$ Million)
Table 50. Asia-Pacific Influenza (Flu) Antiviral Drugs Market Size by Application (2022-2027) & (US$ Million)
Table 51. Asia-Pacific Influenza (Flu) Antiviral Drugs Market Size by Region (2016-2021) & (US$ Million)
Table 52. Asia-Pacific Influenza (Flu) Antiviral Drugs Market Size by Region (2022-2027) & (US$ Million)
Table 53. Latin America Influenza (Flu) Antiviral Drugs Market Size by Type (2016-2021) (US$ Million)
Table 54. Latin America Influenza (Flu) Antiviral Drugs Market Size by Type (2022-2027) & (US$ Million)
Table 55. Latin America Influenza (Flu) Antiviral Drugs Market Size by Application (2016-2021) (US$ Million)
Table 56. Latin America Influenza (Flu) Antiviral Drugs Market Size by Application (2022-2027) & (US$ Million)
Table 57. Latin America Influenza (Flu) Antiviral Drugs Market Size by Country (2016-2021) & (US$ Million)
Table 58. Latin America Influenza (Flu) Antiviral Drugs Market Size by Country (2022-2027) & (US$ Million)
Table 59. Middle East & Africa Influenza (Flu) Antiviral Drugs Market Size by Type (2016-2021) (US$ Million)
Table 60. Middle East & Africa Influenza (Flu) Antiviral Drugs Market Size by Type (2022-2027) & (US$ Million)
Table 61. Middle East & Africa Influenza (Flu) Antiviral Drugs Market Size by Application (2016-2021) (US$ Million)
Table 62. Middle East & Africa Influenza (Flu) Antiviral Drugs Market Size by Application (2022-2027) & (US$ Million)
Table 63. Middle East & Africa Influenza (Flu) Antiviral Drugs Market Size by Country (2016-2021) & (US$ Million)
Table 64. Middle East & Africa Influenza (Flu) Antiviral Drugs Market Size by Country (2022-2027) & (US$ Million)
Table 65. Pfizer Company Details
Table 66. Pfizer Business Overview
Table 67. Pfizer Influenza (Flu) Antiviral Drugs Product
Table 68. Pfizer Revenue in Influenza (Flu) Antiviral Drugs Business (2016-2021) & (US$ Million)
Table 69. Pfizer Recent Development
Table 70. Roche Company Details
Table 71. Roche Business Overview
Table 72. Roche Influenza (Flu) Antiviral Drugs Product
Table 73. Roche Revenue in Influenza (Flu) Antiviral Drugs Business (2016-2021) & (US$ Million)
Table 74. Roche Recent Development
Table 75. Sanofi Company Details
Table 76. Sanofi Business Overview
Table 77. Sanofi Influenza (Flu) Antiviral Drugs Product
Table 78. Sanofi Revenue in Influenza (Flu) Antiviral Drugs Business (2016-2021) & (US$ Million)
Table 79. Sanofi Recent Development
Table 80. Johnson & Johnson Company Details
Table 81. Johnson & Johnson Business Overview
Table 82. Johnson & Johnson Influenza (Flu) Antiviral Drugs Product
Table 83. Johnson & Johnson Revenue in Influenza (Flu) Antiviral Drugs Business (2016-2021) & (US$ Million)
Table 84. Johnson & Johnson Recent Development
Table 85. Merck & Co. (MSD) Company Details
Table 86. Merck & Co. (MSD) Business Overview
Table 87. Merck & Co. (MSD) Influenza (Flu) Antiviral Drugs Product
Table 88. Merck & Co. (MSD) Revenue in Influenza (Flu) Antiviral Drugs Business (2016-2021) & (US$ Million)
Table 89. Merck & Co. (MSD) Recent Development
Table 90. Novartis Company Details
Table 91. Novartis Business Overview
Table 92. Novartis Influenza (Flu) Antiviral Drugs Product
Table 93. Novartis Revenue in Influenza (Flu) Antiviral Drugs Business (2016-2021) & (US$ Million)
Table 94. Novartis Recent Development
Table 95. AbbVie Company Details
Table 96. AbbVie Business Overview
Table 97. AbbVie Influenza (Flu) Antiviral Drugs Product
Table 98. AbbVie Revenue in Influenza (Flu) Antiviral Drugs Business (2016-2021) & (US$ Million)
Table 99. AbbVie Recent Development
Table 100. Gilead Sciences Company Details
Table 101. Gilead Sciences Business Overview
Table 102. Gilead Sciences Revenue in Influenza (Flu) Antiviral Drugs Business (2016-2021) & (US$ Million)
Table 103. Gilead Sciences Recent Development
Table 104. GlaxoSmithKline (GSK) Company Details
Table 105. GlaxoSmithKline (GSK) Business Overview
Table 106. GlaxoSmithKline (GSK) Influenza (Flu) Antiviral Drugs Product
Table 107. GlaxoSmithKline (GSK) Revenue in Influenza (Flu) Antiviral Drugs Business (2016-2021) & (US$ Million)
Table 108. GlaxoSmithKline (GSK) Recent Development
Table 109. Amgen Company Details
Table 110. Amgen Business Overview
Table 111. Amgen Influenza (Flu) Antiviral Drugs Product
Table 112. Amgen Revenue in Influenza (Flu) Antiviral Drugs Business (2016-2021) & (US$ Million)
Table 113. Amgen Recent Development
Table 114. AstraZeneca Company Details
Table 115. AstraZeneca Business Overview
Table 116. AstraZeneca Influenza (Flu) Antiviral Drugs Product
Table 117. AstraZeneca Revenue in Influenza (Flu) Antiviral Drugs Business (2016-2021) & (US$ Million)
Table 118. AstraZeneca Recent Development
Table 119. Bristol-Myers Squibb Company Details
Table 120. Bristol-Myers Squibb Business Overview
Table 121. Bristol-Myers Squibb Influenza (Flu) Antiviral Drugs Product
Table 122. Bristol-Myers Squibb Revenue in Influenza (Flu) Antiviral Drugs Business (2016-2021) & (US$ Million)
Table 123. Bristol-Myers Squibb Recent Development
Table 124. Eli Lilly Company Details
Table 125. Eli Lilly Business Overview
Table 126. Eli Lilly Influenza (Flu) Antiviral Drugs Product
Table 127. Eli Lilly Revenue in Influenza (Flu) Antiviral Drugs Business (2016-2021) & (US$ Million)
Table 128. Eli Lilly Recent Development
Table 129. Teva Company Details
Table 130. Teva Business Overview
Table 131. Teva Influenza (Flu) Antiviral Drugs Product
Table 132. Teva Revenue in Influenza (Flu) Antiviral Drugs Business (2016-2021) & (US$ Million)
Table 133. Teva Recent Development
Table 134. Bayer Company Details
Table 135. Bayer Business Overview
Table 136. Bayer Influenza (Flu) Antiviral Drugs Product
Table 137. Bayer Revenue in Influenza (Flu) Antiviral Drugs Business (2016-2021) & (US$ Million)
Table 138. Bayer Recent Development
Table 139. Novo Nordisk Company Details
Table 140. Novo Nordisk Business Overview
Table 141. Novo Nordisk Influenza (Flu) Antiviral Drugs Product
Table 142. Novo Nordisk Revenue in Influenza (Flu) Antiviral Drugs Business (2016-2021) & (US$ Million)
Table 143. Novo Nordisk Recent Development
Table 144. Allergan Company Details
Table 145. Allergan Business Overview
Table 146. Allergan Influenza (Flu) Antiviral Drugs Product
Table 147. Allergan Revenue in Influenza (Flu) Antiviral Drugs Business (2016-2021) & (US$ Million)
Table 148. Allergan Recent Development
Table 149. Takeda Company Details
Table 150. Takeda Business Overview
Table 151. Takeda Influenza (Flu) Antiviral Drugs Product
Table 152. Takeda Revenue in Influenza (Flu) Antiviral Drugs Business (2016-2021) & (US$ Million)
Table 153. Takeda Recent Development
Table 154. Boehringer Ingelheim Company Details
Table 155. Boehringer Ingelheim Business Overview
Table 156. Boehringer Ingelheim Influenza (Flu) Antiviral Drugs Product
Table 157. Boehringer Ingelheim Revenue in Influenza (Flu) Antiviral Drugs Business (2016-2021) & (US$ Million)
Table 158. Boehringer Ingelheim Recent Development
Table 159. Research Programs/Design for This Report
Table 160. Key Data Information from Secondary Sources
Table 161. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Influenza (Flu) Antiviral Drugs Market Share by Type: 2020 VS 2027
Figure 2. Penetration and Dehulling Inhibitors Features
Figure 3. DNA Polymerase Inhibitors Features
Figure 4. Reverse Transcriptase Inhibitors Features
Figure 5. Protein Inhibitors Features
Figure 6. Neuraminidase Inhibitors Features
Figure 7. Broad-spectrum Antiviral Drugs Features
Figure 8. Global Influenza (Flu) Antiviral Drugs Market Share by Application: 2020 VS 2027
Figure 9. Hospital Case Studies
Figure 10. Clinic Case Studies
Figure 11. Household Case Studies
Figure 12. Others Case Studies
Figure 13. Influenza (Flu) Antiviral Drugs Report Years Considered
Figure 14. Global Influenza (Flu) Antiviral Drugs Market Size (US$ Million), Year-over-Year: 2016-2027
Figure 15. Global Influenza (Flu) Antiviral Drugs Market Size (US$ Million), 2016 VS 2021 VS 2027
Figure 16. Global Influenza (Flu) Antiviral Drugs Market Share by Regions: 2020 VS 2027
Figure 17. Global Influenza (Flu) Antiviral Drugs Market Share by Regions (2022-2027)
Figure 18. Global Influenza (Flu) Antiviral Drugs Market Share by Players in 2020
Figure 19. Global Top Influenza (Flu) Antiviral Drugs Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Influenza (Flu) Antiviral Drugs as of 2020
Figure 20. The Top 10 and 5 Players Market Share by Influenza (Flu) Antiviral Drugs Revenue in 2020
Figure 21. Global Influenza (Flu) Antiviral Drugs Revenue Market Share by Type (2016-2021)
Figure 22. Global Influenza (Flu) Antiviral Drugs Revenue Market Share by Type (2022-2027)
Figure 23. North America Influenza (Flu) Antiviral Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 24. North America Influenza (Flu) Antiviral Drugs Market Share by Type (2016-2027)
Figure 25. North America Influenza (Flu) Antiviral Drugs Market Share by Application (2016-2027)
Figure 26. North America Influenza (Flu) Antiviral Drugs Market Share by Country (2016-2027)
Figure 27. United States Influenza (Flu) Antiviral Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 28. Canada Influenza (Flu) Antiviral Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 29. Europe Influenza (Flu) Antiviral Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 30. Europe Influenza (Flu) Antiviral Drugs Market Share by Type (2016-2027)
Figure 31. Europe Influenza (Flu) Antiviral Drugs Market Share by Application (2016-2027)
Figure 32. Europe Influenza (Flu) Antiviral Drugs Market Share by Country (2016-2027)
Figure 33. Germany Influenza (Flu) Antiviral Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 34. France Influenza (Flu) Antiviral Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 35. U.K. Influenza (Flu) Antiviral Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 36. Italy Influenza (Flu) Antiviral Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 37. Russia Influenza (Flu) Antiviral Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 38. Nordic Influenza (Flu) Antiviral Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 39. Asia-Pacific Influenza (Flu) Antiviral Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 40. Asia-Pacific Influenza (Flu) Antiviral Drugs Market Share by Type (2016-2027)
Figure 41. Asia-Pacific Influenza (Flu) Antiviral Drugs Market Share by Application (2016-2027)
Figure 42. Asia-Pacific Influenza (Flu) Antiviral Drugs Market Share by Region (2016-2027)
Figure 43. China Influenza (Flu) Antiviral Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 44. Japan Influenza (Flu) Antiviral Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 45. South Korea Influenza (Flu) Antiviral Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 46. Southeast Asia Influenza (Flu) Antiviral Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 47. India Influenza (Flu) Antiviral Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 48. Australia Influenza (Flu) Antiviral Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 49. Latin America Influenza (Flu) Antiviral Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 50. Latin America Influenza (Flu) Antiviral Drugs Market Share by Type (2016-2027)
Figure 51. Latin America Influenza (Flu) Antiviral Drugs Market Share by Application (2016-2027)
Figure 52. Latin America Influenza (Flu) Antiviral Drugs Market Share by Country (2016-2027)
Figure 53. Mexico Influenza (Flu) Antiviral Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 54. Brazil Influenza (Flu) Antiviral Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 55. Middle East & Africa Influenza (Flu) Antiviral Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 56. Middle East & Africa Influenza (Flu) Antiviral Drugs Market Share by Type (2016-2027)
Figure 57. Middle East & Africa Influenza (Flu) Antiviral Drugs Market Share by Application (2016-2027)
Figure 58. Middle East & Africa Influenza (Flu) Antiviral Drugs Market Share by Country (2016-2027)
Figure 59. Turkey Influenza (Flu) Antiviral Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 60. Saudi Arabia Influenza (Flu) Antiviral Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 61. UAE Influenza (Flu) Antiviral Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 62. Pfizer Revenue Growth Rate in Influenza (Flu) Antiviral Drugs Business (2016-2021)
Figure 63. Roche Revenue Growth Rate in Influenza (Flu) Antiviral Drugs Business (2016-2021)
Figure 64. Sanofi Revenue Growth Rate in Influenza (Flu) Antiviral Drugs Business (2016-2021)
Figure 65. Johnson & Johnson Revenue Growth Rate in Influenza (Flu) Antiviral Drugs Business (2016-2021)
Figure 66. Merck & Co. (MSD) Revenue Growth Rate in Influenza (Flu) Antiviral Drugs Business (2016-2021)
Figure 67. Novartis Revenue Growth Rate in Influenza (Flu) Antiviral Drugs Business (2016-2021)
Figure 68. AbbVie Revenue Growth Rate in Influenza (Flu) Antiviral Drugs Business (2016-2021)
Figure 69. Gilead Sciences Revenue Growth Rate in Influenza (Flu) Antiviral Drugs Business (2016-2021)
Figure 70. GlaxoSmithKline (GSK) Revenue Growth Rate in Influenza (Flu) Antiviral Drugs Business (2016-2021)
Figure 71. Amgen Revenue Growth Rate in Influenza (Flu) Antiviral Drugs Business (2016-2021)
Figure 72. AstraZeneca Revenue Growth Rate in Influenza (Flu) Antiviral Drugs Business (2016-2021)
Figure 73. Bristol-Myers Squibb Revenue Growth Rate in Influenza (Flu) Antiviral Drugs Business (2016-2021)
Figure 74. Eli Lilly Revenue Growth Rate in Influenza (Flu) Antiviral Drugs Business (2016-2021)
Figure 75. Teva Revenue Growth Rate in Influenza (Flu) Antiviral Drugs Business (2016-2021)
Figure 76. Bayer Revenue Growth Rate in Influenza (Flu) Antiviral Drugs Business (2016-2021)
Figure 77. Novo Nordisk Revenue Growth Rate in Influenza (Flu) Antiviral Drugs Business (2016-2021)
Figure 78. Allergan Revenue Growth Rate in Influenza (Flu) Antiviral Drugs Business (2016-2021)
Figure 79. Takeda Revenue Growth Rate in Influenza (Flu) Antiviral Drugs Business (2016-2021)
Figure 80. Boehringer Ingelheim Revenue Growth Rate in Influenza (Flu) Antiviral Drugs Business (2016-2021)
Figure 81. Bottom-up and Top-down Approaches for This Report
Figure 82. Data Triangulation
Figure 83. Key Executives Interviewed

---